Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 244

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men

Juusola, Jessie L. · 2012 · Annals of Internal Medicine

Abstract

BACKGROUND: Screening and monitoring for chronic kidney disease (CKD) could lead to earlier interventions that improve clinical outcomes. PURPOSE: To summarize evidence about the benefits and harms of screening for and monitoring and treatment of CKD stages 1 to 3 in adults. DATA SOURCES: MEDLINE (1985 through November 2011), reference lists, and expert suggestions. STUDY SELECTION: English-language, randomized, controlled trials that evaluated screening for or monitoring or treatment of CKD and that reported clinical outcomes. DATA EXTRACTION: Two reviewers assessed study characteristics and rated quality and strength of evidence. DATA SYNTHESIS: No trials evaluated screening or monitoring, and 110 evaluated treatments. Angiotensin-converting enzyme inhibitors (relative risk, 0.65 [95% CI, 0.49 to 0.88]) and angiotensin II-receptor blockers (relative risk, 0.77 [CI, 0.66 to 0.90]) reduced end-stage renal disease versus placebo, primarily in patients with diabetes who have macroalbuminuria. Angiotensin-converting enzyme inhibitors reduced mortality versus placebo (relative risk, 0.79 [CI, 0.66 to 0.96]) in patients with microalbuminuria and cardiovascular disease or high-risk diabetes. Statins and β-blockers reduced mortality and cardiovascular events versus placebo or control in patients with impaired estimated glomerular filtration rate and either hyperlipidemia or congestive heart failure, respectively. Risks for mortality, end-stage renal disease, or other clinical outcomes did not significantly differ between strict and usual blood pressure control. The strength of evidence was rated high for angiotensin II-receptor blockers and statins, moderate for angiotensin-converting enzyme inhibitors and β-blockers, and low for strict blood pressure control. LIMITATIONS: Evidence about outcomes was sometimes scant and derived from post hoc analyses of subgroups of patients enrolled in trials. Few trials reported or systematically collected information about adverse events. Selective reporting and publication bias were possible. CONCLUSION: The role of CKD screening or monitoring in improving clinical outcomes is uncertain. Evidence for CKD treatment benefit is strongest for angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers, and in patients with albuminuria combined with diabetes or cardiovascular disease. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-156-8-201204170-00004

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 79

  1. 10.1371/journal.pone.0017502 · DOI · Paper page
  2. 10.1056/NEJMoa1011205 · DOI · Paper page
  3. Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, 60, 65
  4. 10.1086/597095 · DOI · Paper page
  5. 10.1097/QAD.0b013e32830e00f5 · DOI · Paper page
  6. 10.1097/QAD.0b013e328349f067 · DOI
  7. Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb. Mortal Wkly Rep, 57, 1073
  8. 10.1097/OLQ.0b013e3181ce122b · DOI
  9. Arias E, 2007, Natl Vital Stat Rep, 56, 1
  10. 10.1086/386333 · DOI · Paper page
  11. 10.1016/S0891-5520(05)70135-5 · DOI
  12. 10.1086/590501 · DOI · Paper page
  13. 10.1097/QAD.0b013e32826fb6a6 · DOI
  14. 10.1097/00002030-200406180-00010 · doi:10.1097/00002030-200406180-00010
  15. 10.1016/j.vaccine.2009.06.063 · DOI
  16. 10.7326/0003-4819-126-12-199706150-00003 · DOI · Paper page
  17. 10.1086/524686 · DOI
  18. 10.7326/0003-4819-153-12-201012210-00004 · DOI · Paper page
  19. 10.1097/QAD.0b013e328133f285 · DOI · Paper page
  20. 10.1016/S0140-6736(08)61113-7 · DOI · Paper page
  21. 10.1097/00002030-200305020-00012 · DOI
  22. 10.1086/512816 · DOI
  23. 10.1086/429411 · DOI · Paper page
  24. 10.2105/AJPH.93.6.926 · DOI · Paper page
  25. 10.1097/00002030-200207260-00010 · DOI · Paper page
  26. 10.7326/0003-4819-145-6-200609190-00005 · DOI · Paper page
  27. 10.1097/00126334-200404150-00011 · DOI · Paper page
  28. 10.1097/01.aids.0000238410.67700.d1 · DOI
  29. 10.1097/00007435-199808000-00006 · DOI
  30. 10.1056/NEJMsa042657 · DOI · Paper page
  31. 10.1056/NEJMoa1105243 · DOI · Paper page
  32. 10.1016/S0140-6736(08)61115-0 · DOI · Paper page
  33. 10.1056/NEJM200003303421303 · DOI · Paper page
  34. 10.1126/science.280.5371.1889 · DOI · Paper page
  35. 10.1001/jama.280.13.1161 · DOI · Paper page
  36. 10.1097/01.qai.0000194234.31078.bf · DOI
  37. 10.7326/0003-4819-146-8-200704170-00010 · DOI · Paper page
  38. Sanchez T, 2006, MMWR Surveill Summ, 55, 1
  39. 10.1007/s11524-006-9135-5 · DOI
  40. 10.1097/QAI.0b013e3181ee4c62 · DOI
  41. 10.1007/s10461-009-9582-6 · DOI
  42. 10.1097/01.qai.0000151079.33935.79 · DOI · Paper page
  43. 10.7326/0003-4819-125-4-199608150-00001 · DOI · Paper page
  44. 10.7326/0003-4819-134-1-200101020-00010 · DOI · Paper page
  45. 10.1056/NEJM200103153441107 · DOI · Paper page
  46. 10.1097/01.mlr.0000228021.89490.2a · DOI · Paper page
  47. 10.1097/MLR.0b013e31821b34c0 · DOI · Paper page
  48. 10.1097/00002030-199905280-00013 · DOI
  49. 10.1097/01.qai.0000243090.32866.4e · DOI
  50. 10.1377/hlthaff.23.4.176 · DOI · Paper page
  51. 10.1177/00333549081230S307 · DOI · Paper page
  52. 10.7326/0003-4819-145-11-200612050-00004 · DOI · Paper page
  53. Branson BM, 2006, MMWR Recomm Rep, 55, 1
  54. 10.1001/jama.300.5.555 · DOI · Paper page
  55. 10.1089/apc.2010.0222 · DOI
  56. 10.1007/s11904-010-0057-1 · DOI
  57. 10.1097/QAI.0b013e3181e19a54 · DOI · Paper page
  58. 10.1089/apc.2010.0173 · doi:10.1089/apc.2010.0173
  59. 10.1097/QAI.0b013e31818d5a27 · DOI · Paper page
  60. 10.1097/QAI.0b013e31815e4041 · DOI · Paper page
  61. 10.1007/s11136-005-8485-x · doi:10.1007/s11136-005-8485-x
  62. 10.7326/0003-4819-154-3-201102010-00007 · DOI · Paper page
  63. 10.1371/journal.pmed.1000423 · DOI
  64. 10.1097/00002030-199510000-00001 · DOI
  65. 10.1177/0272989X9301300202 · DOI · Paper page
  66. 10.1001/jama.1997.03550230061038 · DOI
  67. 10.7326/0000605-200912150-00157 · DOI
  68. 10.1016/j.vaccine.2004.12.033 · DOI
  69. 10.1046/j.1524-4733.2003.00213.x · DOI
  70. 10.7326/0003-4819-139-2-200307150-00011 · DOI
  71. 10.1097/00042560-199709010-00009 · DOI · Paper page
  72. 10.1177/0272989X02238300 · DOI · Paper page
  73. 10.1097/MLR.0b013e31803dce05 · DOI
  74. 10.1177/0272989X06290495 · DOI · Paper page
  75. 10.1097/QAD.0b013e328010c7d0 · DOI
  76. 10.1001/archinte.1996.00440040066007 · DOI
  77. 10.1016/S0002-9343(00)00583-0 · doi:10.1016/s0002-9343(00)00583-0
  78. 10.1007/s11908-006-0008-6 · DOI · Paper page
  79. 10.1056/NEJMsa042088 · DOI · Paper page

Cited by

See all 244

Metadata

Authors
Juusola, J. L.
Venue
Annals of Internal Medicine
Published
2012-04-17
Volume
156
Issue
8
Pages
541
ISSN
0003-4819 (ISSN-L)
OpenAlex
W2072871688
Cited by
244
References
21
FWCI
25.90
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. https://app.cochat.ai/papers/10.7326/0003-4819-156-8-201204170-00004
The paper
Juusola, J. L. (2012). The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-156-8-201204170-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.